An emerging Ferroptosis-Correlated Genes Character for Renal Cell Carcinoma

Lin Zhang¹, Ying Zhou¹, Jiashun Zhou²

1 State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional

Chinese Medicine, 10 Poyanghu Road, Jinghai, Tianjin 301617, P. R. China.

2 Tianjin Jinghai District Hospital, 14 Shengli Road, Jinghai, Tianjin 301699, P. R. China.

Abstract: Renal Cell Carcinoma (RCC), composed of various subtypes, faces a prognostic prediction challenge. Ferroptosis, an emerging cell death form, has been considered as a vital factor for the development of cancer. However, it remains a further exploration of the predictive value for ferroptosis-correlated genes in RCC. In our work, we paid attention to the gene expression data related to clinical profiles of RCC patients which derived from public databases, TCGA and ICGC. The least absolute shrinkage and selection operator (LASSO) Cox regression performed to establish an optimally predictive model based on the TCGA data. The RCC patients derived from ICGC applied to the validation of the predictive model above. Under expectation, our observation indicated that major ferroptosis-correlated genes (75%) expressed significantly between tumorous and adjacently normal cells in the TCGA cohort. Combined with the differentially expressed genes (DEGs) (P< 0.05) and overall survival (OS), there were twenty-seven genes eventually approached the subsequent analyses. With the optimal 12-genes model screened by LASSO analysis, we aimed to classify RCC patients into the high-risk or low-risk groups based on the median scores. And we created a novel predictive model based on the 12-genes' risk score. Compared with the two groups, our work discovered that patients in the high-risk group presented more observably shrunken OS than the low (P < 0.05). Through the multivariate cox regression, the predictive model became an independent risk factor in OS (HR =2.053, P<0.001). Moreover, the receiver operating characteristic (ROC) curve proved the significantly predictive value for our predictive model. Functional research unexpectedly showed the immune cells and immune

function pathways enriched differently, which emphasized the immune role for the progress of RCC. In a word, an emerging ferroptosis-correlated signature might be popular for medical prediction in RCC. The targeted treatment on ferroptosis may be a potential schedule for RCC.

Keywords: Renal cell carcinoma, Lasso Cox regression, ferroptosis, TCGA, ICGC, prognostic model

1 Introduction

Renal Cancer, the ninth most common carcinoma around the world[1], accounted for 3% of adult malignancies and had been blamed for 13680 deaths from 65 150 RCC patients in the US in 2013[2]. RCC accounts for 80% of all renal cancers and is famous for late-stage recurrence[3,4]. During the recent two decades, even if the diagnosis and management of RCC were improving, RCC remains one of the most lethally renal malignancies[5]. Smoking, obesity and high blood pressure remain established risk factors for RCC. During 1992 and 2015, one research-based on the SEER database indicated that the incidence of RCC was increasing globally every year[6].

Ferroptosis, an emerging iron-relied pattern of cell death, is activated by the fatal recruitment of lipid peroxidation which significantly increased in the cytoplasm, lipid ROS and mitochondrial membrane density [7,8]. In the recent decade, ferroptosis has become an emerging induction of alternative therapeutics to result in cancer cells' death, particularly in resistant malignancies[9]. Published studies have illustrated that ferroptosis serves a crucial function in the evolution of RCC. When glutamine and cysteine transformed to glutathione (GSH), ferroptosis accompanied by up-regulated lipid peroxidation[10]. Von Hippel-Lindau (VHL) gene[11], the most frequent genetic event observed in RCC, attracted numerous scholars' attention for the potential therapeutic in RCC[12-15]. Previous research has shown deprivation of glutamine and cysteine might provide the possibility for VHL/ HIF-related treatment of RCC[16]. Glutamine and cystine were essential for the expression of GSH, which emphasized

the deprivation of glutamine and cystine could weaken the expressional GSH accompanied by the alleviated growth in the MYC-dependent RCC[10]. All these shreds of evidence stressed above the relation of ferroptosis-correlated genes and RCC.

In this work, we initially downloaded genetic expression data connected with clinical profiles of RCC patients via public databases TCGA and ICGC. Second, we modelled a ferroptosis-correlated prognostication accompanied with DEGs in the TCGA cohort and verified the predictive value in the ICGC cohort. We established a predictive model based on the relationship between OS and risk. Eventually, our study further attracted to the enrichment of mechanisms to investigate the potential pathway for ferroptosis-correlated genes with RCC.

2 Materials and Methods

2.1 TCGA-RCC data set and ICGC (RECA-EU) data set

Up to September 24, 2020, we downloaded the gene sequencing data related to clinical information of 1023 RCC patients from the public database the TCGA (https://portal.gdc.cancer.gov/). According to the pathological pattern, we can divide the RCC patients from TCGA into four types such as KIRC, KIRP, KICH and SARC. For the verification of TCGA cohort, the ICGC(https://dcc.icgc.org) cohort provided another 475 tumorous patients. It provided a regulated method in the "limma" R package to average the gene expression value. These prognostic samples primarily derived from US (TCGA), and the verified were from France (ICGC). Because both cohorts came from public databases and obeyed general principle of TCGA and ICGC databases, these observations possessed immunity for approval of local ethics committees. Finally, we retrospected 60 ferroptosis-correlated genes originating from the previous researches [8,9,17-19] in Supplementary Table 1.

2.2 Foundation and verification for genetic characteristics of the

ferroptosis-prognostic model

Strawberry Perl was used to transforming primary data to the genetic matrix of expression. The "limma" R package played a crucial role to identify the DEGs

between tumorous and normal cells with a false discovery rate (FDR) < 0.05 in the TCGA cohort. Combined the clinical information and gene expression, this study explored the ferroptosis-genetic characteristics of OS by univariate Cox analysis. We used Benjamini & Hochberg (BH) correction to adjust P values. The STRING(version 11.0) [20] database originated an interacting genes (IEs) network for the overlapping DEGs and OS. The LASSO-penalized Cox regression analysis, involved in establishing a predictive model, can decrease the statistical risk of over-fitting[21,22]. The R package "glmnet" was used to select optimally genetic variables with LASSO formula. Through the normalized matrix of alternative IEs, we screened the independent variables which contained OS and the alive status of TCGA patients. Patients' risk scores were calculated with the basement of the adjusted expression value for the corresponding coefficients (CC). The risk-score formula was constructed as follows[19]: score= e^{sum (gene's expression *CC)}. With the median value of the statistical score, the RCC patients classified into high-risk or low-risk groups.

For verification of the prognostic model, PCA was applied into the "prcomp" module via the R package "stats". Furthermore, the t-SNE analysis was carried out to illustrate the trend of risk-score groups via R package "Rtsne". The R package "survivalROC" analyzed time□reliant ROC to test the potential value of the genetic characteristics.

2.3 Enrichment analysis

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were constructed by R package "clusterProfiler". Through the risk-score, several genes were selected to accomplish the immune analysis which contained 16 immune cells and 13 immune pathways with single-sample gene set enrichment (ssGSEA) [23] via the R package "gsva". Supplementary Table 2 described the infiltrating gene.

2.4 Statistical analysis

Student's t-test was utilized to identify a genetic difference between tumorous and normal cells. The Chi-squared test performed proportions in contrast.

Mann-Whitney U test, regulated by the BH analysis, applied to enrich the ssGSEA analysis of immune cells and pathways.

Kaplan-Meier analysis accomplished the OS contrast. To screen independent risk-factors of OS, we adopted univariate and multivariate Cox regression analysis. All statistic accomplished via R software (Version 4.0.0). We take P-value as statistical significance until less than 0.05.

3 Results

The establishment of predictive model based on TCGA cohort and verification based on the ICGC cohort just like Fig 1. The present study contained1493 RCC patients derived from 1023 TCGA-RCC cohort, 475 RCC patients derived from ICGC (RECA-EU) cohort. Under the initial screening condition, this work finally involved 881 RCC patients from TCGA and 470 from ICGC. These RCC patients' clinical information summarized in Table 1.

Fig 1. Flow diagram for inclusion and analysis of RCC patients.

Table 1. Clinical information of RCC patients from TCGA and ICGC cohort.

3.1 Recognition of predictive ferroptosis-connected DEGs in the TCGA cohort

Combined ferroptosis-correlated genes with TCGA cohort, we unexpectedly discovered all members of these genes expressed between tumoral and adjacently normal cells in the kidney of RCC. Then the DEGs illustrated that there were 45(45/60,75%) ferroptosis-correlated genes serve a statistically significant function in RCC. According to the OS for the univariate Cox regression analysis, there were 27 genes significantly associated with the clinical data of RCC (Fig. 2a). Compared with the tumoral and normal cells, these 27-genes expressed considerably (Fig. 2b-c). These 27 genes' correlation network indicated G6PD was the core of the candidate

(Fig. 2e).

Fig 2. The ferroptosis-correlated genes for RCC patients in the TCGA cohort. a.

Venn diagram of the interaction between tumoral and normal tissue for both statistical difference and OS. b. The heat map clustering for 27 genes. c. Forest map illustrates the correlation between the univariate analysis and OS. d. STRING database provided the PPI network to demonstrate the association with the candidate genes. e. The correlation network among candidate genes.

3.2 Formation of a predictive model with TCGA cohort

The predictive model, screened from expression profiles of 27 genes mentioned above, constructed a novel risk-score type with LASSO Cox regression analysis. According to the value of λ , our study identified a 12-genes signature composed of seven genes with high expression and five genes with low expression. These 12 genes correlated with survival analysis, and the best cut-off expression value indicated an excellent prognosis (P < 0.05). The follows show the formula that we calculated the risk score: e (0.043 * expressive value of SLC7A11 + 0.116 * expressive value of G6PD + 0.106 * expressive value of CD44 - 0.004 * expression value of ATP5MC3 + 0.138 * expression value of NOX1 + 0.545 * expression value of FANCD2 + 0.009 * expressive value of PTGS2 - 0.033 * expressive value of ACO1 + 0.136 * expressive value of ABCC1 + 0.159* expressive value of CHAC1 + 0.061 * expressive value of MT1G - 0.301 * expressive value of HMGCR - 0.161 * expressive value of GLS2 - 0.214* expressive value of PEBP1). RCC patients classified into the high-risk group (n=438) or the low-risk group (n=439) with the median cut-off threshold (Fig. 3a). Based on the predictive model, the higher risk group statistically reacted with a higher grade of the tumor. Through t-SNE and PCA analyses, we found patients with different risk-score expressed with different directions (Fig. 3b-c). In the TCGA cohort, high risk-score patients of RCC existed a higher risk of death than the low (Fig. 3d). Similarly, the survival curve showed that patients in the high-risk group possessed more decreased survival time than the low (Fig. 3e, P<0.001). ROC curve, based on the predictively time-dependent model of OS, diagrammatic the area under the curve (AUC) reached 0.755 at one year, 0.739 at two years, and 0.731 at three years (Fig. 3f).

Fig.3 Prognostic model based on the 12-genes in the TCGA cohort. a. The distribution based on a threshold of the risk-scores. b. PCA analysis based on the risk-score groups. c. t-SNE plots based on the risk-score groups. d. The distributions between survival time and increasing risk-score. e. Kaplan-Meier survival curves for the two groups between survival probability and survival time. f. AUC curves tested the predictive value of the prognostic model.

3.3 Validation based on the 12-genes in the ICGC cohort

The prognostic model had shown the predictive value for the RCC above. To test the reliability of the model, we also classified RCC patients from ICGC into high-risk or low-risk groups according to the threshold calculated with the similar formula of TCGA cohort. Because of the difference of the two cohorts, this median threshold enacted with the ICGC cohort (Fig. 4a). Consistently, PCA and t-SNE analysis, obtained from the ICGC cohort, showed that patients in different groups distributed in different trends (Fig. 4b-c). The distributions between OS and risk score were not so remarkable like the TCGA cohort (Fig. 4d), but it remained significant. Similarly to the TCGA cohort, the survival curve showed that patients in the high-risk group possessed more decreased survival time than the low (Fig. 4e, P<0.05). Otherwise, the AUC based on the 12-genes was 0.733 at one year,0.645 at two years, and 0.565 at three years (Fig. 4f).

Fig 4. Validation based on the 12-genes in the ICGC cohort. a. The distribution based on a threshold of the risk-scores. b. PCA analysis based on the risk-score groups. c. t-SNE plots based on the risk-score groups. d. The distributions for the two groups between survival time and increasing risk-score. e. Kaplan-Meier survival curves for

the two groups between survival probability and survival time. f. AUC of time-dependent ROC curves tested the predictive value of the prognostic model.

3.4 Independent predictive value and immune analysis based on the 12-genes in the TCGA cohort.

To test whether our predictive model became an independent risk-factor for OS, Cox regression analysis performed the clinical variables. Not only in univariate Cox regression analysis (HR= 2.796, 95% CI =2.252-3.471, P< 0.001 Fig. 5a), but also in multivariate Cox regression analysis (HR =2.053, 95% CI = 1.625-2.592, P<0.001 Fig.5b), our prognostic model had shown that our predictive model closely associated with OS in TCGA cohort.

By quantifying the enrichment of various immune cell subpopulations and immune pathways with ssGSEA, we attracted further to investigate the association between the two groups and immune status. Unexpectedly, we found other contents of the immunologic process were significant in the TCGA cohort except for the NK cell and IFN of Type II (adjusted P< 0.05, Fig. 5c-d). Interestingly, the DEGs were also obviously enriched in various and immunity-correlated processes of biology (P. adjust < 0.05, Fig. 5c). We speculated ferroptosis-immune function and cells play an essential role in the development of RCC above.

Fig 5. Independent prognostic value and immune analysis of the 12-gene signature. a. Univariate analysis of clinical variables of the TCGA cohort. b. Multivariate analysis of clinical variables of the TCGA cohort. c. Enrichment of various immune pathways. D. Enrichment of various immune cells.

3.5 GO and KEGG analysis both in TCGA and ICGC cohorts

To illustrate the biological functions and pathways which correlated with the predictive model, we dedicated the DEGs between the two groups to perform GO

enrichment and KEGG pathway. As expectedly, DEGs involved in two molecularly iron-correlated functions, iron transmembrane transport pathway and iron binding (P. revised< 0.05). In KEGG pathways, there was a common enrichment (protein digestion and absorption pathway) both in TCGA and ICGC cohort (adjusted P< 0.05, Fig. 6c-d).

Fig 6. The consequence of enrichment GO (a, b) and KEGG analysis (c, d). The GO enrichment and KEGG pathways in the TCGA cohort (a, c) and ICGC cohort (b, d). The red rectangles show the overlapped enrichments or paths both in the two cohorts.

4 Discussion

In this study, we paid attention to investigate the 60 ferroptosis-correlated genes in RCC tumoral cells and their connection with OS. With the LASSO Cox regression analysis to screen a novel predictive model interacting 12 ferroptosis-related genes. To verify whether the predictive model possesses prediction, this work involved an external cohort via the same methods. Functional analysis of GO, KEGG, and immune-related pathways applied to reveal the potential mechanisms of RCC development.

The previous researchs[24] had shown that ferroptosis might serve a crucial function in RCC, but the ferroptosis-correlation with RCC patients' OS remains unknown. TAZ[25], a hippo pathway effector, triggered a density-regulated ferroptosis through regulating EMP1-NOX4 which indicated a new therapeutic potential for RCC. Compared among 177 types of cancer cells, a recent study shown that RCC is most particularly susceptible to GPX4-regulated ferroptosis[26]. Thus, GPX4's ferroptosis is an essential regulator of RCC[26]. Sorafenib, a ferroptosis inducer to treat RCC, indirectly supported the existence of ferroptosis in RCC with clinical effectiveness[24].

It amazed us that major ferroptosis-connected genes (75%) significantly

> expressed compared tumoral with adjacent normal cells, and 27 genes interacted in the Cox regression analysis. Our research showed the potential ferroptosis-target in RCC and the opportunity of creating a predictive model with ferroptosis-correlated genes. This work indicated a prognostic model composed of 12 ferroptosis-correlated genes (ATP5MC3, CD44, NOX1, FANCD2, PTGS2, ACO1, ABCC1, CHAC1, MT1G, HMGCR, GLS2, PEBP1). According to the previous study[9,27], we roughly classified these genes into four categories as follows, lipid metabolism (CD44, PTGS2, HMGCR, PEBP1), iron metabolism (FANCD2, ACO1, MT1G), energy metabolism (ATP5MC3, ABCC1, GLS2) and (anti) oxidant metabolism (NOX1, CHAC1). A meta-analysis reported that CD44 was a prognostic factor in RCC and high CD44 expression connected with high cancer grade, recurrence and poor prognosis[28]. VHL, Vol Hippel-Lindau tumour suppressor gene, accomplished its tumour suppressor action with the restriction of p22phox-based Nox4/Nox1 NADPH oxidase-dependent pathway[29]. GKT137831, a sensitive NOX1/4 isoform inhibitor, observably alleviated ROS and lipid ROS which provided a novel perspective into the molecular-ferroptosis in RMS[30]. FANCD2 and HMGCR [31], reversing the regulation of ferroptosis, were involved in a survival model among five risk-related genes which existed potential prognostic biomarkers and therapeutic to ccRCC[32]. COX-2, regulated by PTGS2, expressed highly in RCC, which might be a trigger that served a crucial function in the development of RCC and warranted further research[33]. ABCC1, as a novel factor of miR-210-3p, negatively regulated miR-210-3p to ease drug-sensitivity of RCC cells. And inhibition of ABCC1 could reverse the effect of miR-210-3p knockdown drug-resistance in RCC cells[34]. PEBP1 can regulate lipoxygenase of lipid death to trigger ferroptosis[35]. Through GCN2-eIF2 α -ATF4 pathway, the CHAC1 degradation of glutathione can enhance ferroptosis in breast cancer cells[36]. The published study had proved that MT1G advocated the development of RCC as promoter methylation [37]. It had confirmed that GLS2 play a potential connection of iron-metabolism and ferroptosis to p53tumor suppression[38]. Whether these 12 ferroptosis-genes play an essential role in RCC

patients' prognosis via the development of immune ferroptosis remains to be explained, few researches on these genes except CD44 and ABCC1 had been represented in RCC.

Although it is more and more intense for the ferroptosis-mechanisms of tumour in the recent decade, the potential mechanisms connected tumoral immunity and ferroptosis remains dimness. With the basement of DEGs between high and low risk-score groups, our study applied to GO analysis and amazedly detected that various immune-correlatedly biological pathways enriched. And an expression of different group significantly transformed via immune cells and immune function.

Over the past decade or so, medical treatment for RCC has transformed a nonspecific immune therapy, to targeted medicine against VEGF, and now to an emerging immunotherapy treatment[39] and immune-checkpoint inhibitor have been approved to cure patients with advanced RCC. The tumor immune microenvironment has confirmed to correlate with ccRCC[40]. Tregs and monocytes, both belonged to immune cells, indicated independent risk factors for prognosis in patients with RCC[41].In our study, other types of 15 immune cells and 12 functional immune pathways express significantly in the two groups except for NK cell and the IFN type II. IFN type II independent enhance the up-regulation of B cell TLR7 by NK cells[42], which mean NK cells regulated the IFN type II[43]. It was similar to our research, published study illustrated that standard type VHL in human RCC alleviated in NK cells sensitivity[11]. So primary RCC patients expressed no difference in NK cells to IFN type II except the VHL mutated[11].One possible perspective showed that macrophages transported unclear signals, such as lipid factors, recruited antigen-presenting cells (APCs) to the site of ferroptosis [44]. Besides, the high-risk score groups in our study possess a higher possibility of macrophages and Treg cells. As previously described that up-regulated tumoral macrophages [45,46]or Treg cells [47] are correlated with poor prognosis in RCC patients because of immune invasion. Th17 and CD8 cells, Tregs' subsets, associated positively with improved survival, whereas Th2 cells associated with negative outcomes in ccRCC[47]. The expression

of CD4+ and CD25+ regulatory Tregs increased in RCC patients[48], and recombinant IL-2 restrained the number of Tregs in peripheral blood of patients with metastatic RCC via the inhibition of CD4+ and CD25+[49]. In summary, not only our ferroptosis-work but also other studies had confirmed the intense relevance between RCC and immunity. And in our research, there was no different for the NK cells and subsequent IFN type II.

There remained some limitations to our study. Our conclusion required been validated by clinically randomized controlled trials or real-world prospective data because our samples derived from public databases. Second, it is inevitable to ignore some prominent prognostic genes because we merely considered a single signature to build this model of RCC. Importantly, we highlighted the connection for prognostic model and immune activity required experimental verification.

In a word, we reported a novelly predictive model based on 12 ferroptosis-correlated genes which were independently associated with OS in both the TCGA and ICGC cohorts. The potential pathways between ferroptosis-correlated genes and immunity in RCC warranted further investigation.

Disclosure Statement

No competing financial interests exist.

Funding Information

We received no funding for this article.

Ethics approval

We had waivers of ethics approval because the data came from public database.

references

1. Jonasch E, Gao J, Rathmell WK (2014) Renal cell carcinoma. Bmj 349:g4797.

doi:10.1136/bmj.g4797

2. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63

(1):11-30. doi:10.3322/caac.21166

3. Capitanio U, Montorsi F (2016) Renal cancer. Lancet 387 (10021):894-906.

doi:10.1016/s0140-6736(15)00046-x

4. Cognard N, Anglicheau D, Gatault P, Girerd S, Essig M, Hurault de Ligny B, Le Meur Y, Le

Roy F, Garrouste C, Thierry A, Colosio C, Rivalan J, Sayegh J, Choukroun G, Moulin B,

Caillard S (2018) Recurrence of Renal Cell Cancer After Renal Transplantation in a

Multicenter French Cohort. Transplantation 102 (5):860-867.

doi:10.1097/tp.000000000002009

5. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, Gore JL, Sun M, Wood C,

Russo P (2019) Epidemiology of Renal Cell Carcinoma. Eur Urol 75 (1):74-84.

doi:10.1016/j.eururo.2018.08.036

6. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH (2019) Trends in

Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A

SEER-Based Study. Clin Genitourin Cancer 17 (1):46-57.e45. doi:10.1016/j.clgc.2018.10.002

7. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN,

Bauer AJ, Cantley AM, Yang WS, Morrison B, 3rd, Stockwell BR (2012) Ferroptosis: an

iron-dependent form of nonapoptotic cell death. Cell 149 (5):1060-1072.

doi:10.1016/j.cell.2012.03.042

8. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush Al, Conrad M, Dixon SJ, Fulda S,

Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M,

Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV,

Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: A Regulated Cell Death Nexus

Linking Metabolism, Redox Biology, and Disease. Cell 171 (2):273-285.

doi:10.1016/j.cell.2017.09.021

9. Hassannia B, Vandenabeele P, Vanden Berghe T (2019) Targeting Ferroptosis to Iron Out Cancer. Cancer Cell 35 (6):830-849. doi:10.1016/j.ccell.2019.04.002

10. Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell

M, Downward J, Felsher DW, Peck B, Schulze A (2018) The glutathione redox system is

essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell

carcinoma. Oncogene 37 (40):5435-5450. doi:10.1038/s41388-018-0315-z

11. Trotta AM, Santagata S, Zanotta S, D'Alterio C, Napolitano M, Rea G, Camerlingo R,

Esposito F, Lamantia E, Anniciello A, Botti G, Longo N, Botti G, Pignata S, Perdonà S, Scala S

(2018) Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific

natural killer (NK) cytotoxicity. J Exp Clin Cancer Res 37 (1):297.

doi:10.1186/s13046-018-0952-7

12. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K (2005) Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13 (5):859-864

Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC, van Engeland M
(2018) Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol 15
(7):430-451. doi:10.1038/s41585-018-0023-z

14. Qin C, Cao Q, Ju X, Wang M, Meng X, Zhu J, Yan F, Li P, Ding Q, Chen J, Gu M, Zhang W, Yin C, Zhang Z (2012) The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol 23 (4):981-989. doi:10.1093/annonc/mdr325 15. Yu Y, Yu Q, Zhang X (2019) Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma. Drug Discov Today 24 (12):2332-2340. doi:10.1016/j.drudis.2019.09.008 16. Lai Y, Zeng T, Liang X, Wu W, Zhong F, Wu W (2019) Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. Cancer Cell Int 19:221.

doi:10.1186/s12935-019-0939-2

17. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575 (7784):688-692. doi:10.1038/s41586-019-1705-2

18. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Goya Grocin A, Xavier da Silva TN, Panzilius E, Scheel CH, Mourão A, Buday K, Sato M, Wanninger J, Vignane T, Mohana V, Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W, Schulze A, O'Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli JPF, Conrad M (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575

(7784):693-698. doi:10.1038/s41586-019-1707-0

19. Liang JY, Wang DS, Lin HC, Chen XX, Yang H, Zheng Y, Li YH (2020) A Novel

Ferroptosis-related Gene Signature for Overall Survival Prediction in Patients with

Hepatocellular Carcinoma. Int J Biol Sci 16 (13):2430-2441. doi:10.7150/ijbs.45050

20. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark

M, Muller J, Bork P, Jensen LJ, von Mering C (2011) The STRING database in 2011:

functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res

39 (Database issue):D561-568. doi:10.1093/nar/gkq973

> 21. Simon N, Friedman J, Hastie T, Tibshirani R (2011) Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. J Stat Softw 39 (5):1-13. doi:10.18637/jss.v039.i05

22. Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16

(4):385-395. doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3

23. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic

properties of tumors associated with local immune cytolytic activity. Cell 160 (1-2):48-61.

doi:10.1016/j.cell.2014.12.033

24. Yu H, Guo P, Xie X, Wang Y, Chen G (2017) Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. J Cell Mol Med 21 (4):648-657.

doi:10.1111/jcmm.13008

25. Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D, Chi JT (2019) The Hippo

Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Cell Rep 28

(10):2501-2508.e2504. doi:10.1016/j.celrep.2019.07.107

26. Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah

JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL,

Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156

(1-2):317-331. doi:10.1016/j.cell.2013.12.010

27. Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki

M, Sukhatme VP, Kufe D (2016) Functional interactions of the cystine/glutamate antiporter,

CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget 7

(11):11756-11769. doi:10.18632/oncotarget.7598

> 28. Li X, Ma X, Chen L, Gu L, Zhang Y, Zhang F, Ouyang Y, Gao Y, Huang Q, Zhang X (2015) Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep 5:13157. doi:10.1038/srep13157

29. Block K, Gorin Y, Hoover P, Williams P, Chelmicki T, Clark RA, Yoneda T, Abboud HE

(2007) NAD(P)H oxidases regulate HIF-2alpha protein expression. J Biol Chem 282

(11):8019-8026. doi:10.1074/jbc.M611569200

30. Dächert J, Ehrenfeld V, Habermann K, Dolgikh N, Fulda S (2020) Targeting ferroptosis in rhabdomyosarcoma cells. Int J Cancer 146 (2):510-520. doi:10.1002/ijc.32496

31. Song X, Xie Y, Kang R, Hou W, Sun X, Epperly MW, Greenberger JS, Tang D (2016)

FANCD2 protects against bone marrow injury from ferroptosis. Biochem Biophys Res

Commun 480 (3):443-449. doi:10.1016/j.bbrc.2016.10.068

32. Wu G, Wang Q, Xu Y, Li Q, Cheng L (2020) A new survival model based on

ferroptosis-related genes for prognostic prediction in clear cell renal cell carcinoma. Aging

(Albany NY) 12 (14):14933-14948. doi:10.18632/aging.103553

33. Mungan MU, Gurel D, Canda AE, Tuna B, Yorukoglu K, Kirkali Z (2006) Expression of

COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell

carcinoma. Eur Urol 50 (1):92-97; discussion 97. doi:10.1016/j.eururo.2005.12.039

34. Li S, Yang J, Wang J, Gao W, Ding Y, Ding Y, Jia Z (2018) Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1. Cell

Biosci 8:9. doi:10.1186/s13578-018-0209-3

35. Wenzel SE, Tyurina YY, Zhao J, St Croix CM, Dar HH, Mao G, Tyurin VA, Anthonymuthu

TS, Kapralov AA, Amoscato AA, Mikulska-Ruminska K, Shrivastava IH, Kenny EM, Yang Q,

> Rosenbaum JC, Sparvero LJ, Emlet DR, Wen X, Minami Y, Qu F, Watkins SC, Holman TR, VanDemark AP, Kellum JA, Bahar I, Bayır H, Kagan VE (2017) PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell 171 (3):628-641.e626. doi:10.1016/j.cell.2017.09.044

36. Chen MS, Wang SF, Hsu CY, Yin PH, Yeh TS, Lee HC, Tseng LM (2017) CHAC1

degradation of glutathione enhances cystine-starvation-induced necroptosis and ferroptosis in

human triple negative breast cancer cells via the GCN2-elF2 α -ATF4 pathway. Oncotarget 8

(70):114588-114602. doi:10.18632/oncotarget.23055

37. Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Teh BT, Latif

F, Maher ER (2008) Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer 98 (2):496-501.

doi:10.1038/sj.bjc.6604180

38. Jennis M, Kung CP, Basu S, Budina-Kolomets A, Leu JI, Khaku S, Scott JP, Cai KQ,

Campbell MR, Porter DK, Wang X, Bell DA, Li X, Garlick DS, Liu Q, Hollstein M, George DL,

Murphy ME (2016) An African-specific polymorphism in the TP53 gene impairs p53 tumor

suppressor function in a mouse model. Genes Dev 30 (8):918-930.

doi:10.1101/gad.275891.115

39. Barata PC, Rini BI (2017) Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin 67 (6):507-524. doi:10.3322/caac.21411

40. Eich ML, Chaux A, Mendoza Rodriguez MA, Guner G, Taheri D, Rodriguez Pena MDC, Sharma R, Allaf ME, Netto GJ (2020) Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma. Histopathology 76 (3):423-432.

doi:10.1111/his.13987

41. Zhu G, Pei L, Yin H, Lin F, Li X, Zhu X, He W, Gou X (2019) Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications. Oncol Lett 18

(5):5235-5242. doi:10.3892/ol.2019.10896

42. Sinha S, Guo Y, Thet S, Yuan D (2012) IFN type I and type II independent enhancement of

B cell TLR7 expression by natural killer cells. J Leukoc Biol 92 (4):713-722.

doi:10.1189/jlb.0212064

43. Temizoz B, Kuroda E, Ohata K, Jounai N, Ozasa K, Kobiyama K, Aoshi T, Ishii KJ (2015) TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur J Immunol 45 (4):1159-1169. doi:10.1002/eji.201445132

44. Friedmann Angeli JP, Krysko DV, Conrad M (2019) Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer 19 (7):405-414. doi:10.1038/s41568-019-0149-1

45. Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles Al, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik

> M, Chan DW, Nesvizhskii AI, Wang P, Zhang H (2019) Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 179 (4):964-983.e931. doi:10.1016/j.cell.2019.10.007

46. Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG, Jr., Choueiri TK, Van Allen EM (2018) Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359 (6377):801-806. doi:10.1126/science.aan5951

47. Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D,

Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD,

Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH,

Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA (2016) Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol 17 (1):231.

doi:10.1186/s13059-016-1092-z

48. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (7):1169-1177. doi: 10.1200/jco.2005.03.6830

49. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 (12):3623-3633.

doi:10.1172/jci25947

	TCGA cohort	RECA-EU
No. of patients	881	470
Age (median, range)	60(17-90)	62(23-86)
Gender (%)		
Female	288(32.7%)	194(41.3%)
Male	593(67.3%)	276(58.7%)
Grade(%)		
Grade 1	14(1.6%)	NA
Grade 2	227(25.8%)	NA
Grade 3	206(23.4%)	NA
Grade 4	75(8.5%)	NA
Grade 5	5(0.6%)	NA
unknown	354(40.2%)	NA
Stage(%)		
Ι	456(51.8%)	226(48.1%)
Π	102(11.6%)	53(11.3%)
III	188(21.3%)	110(23.4%)
IV	103(11.7%)	68(14.5%)
unknown	32(3.6%)	13(2.8%)
Survival status		
OS days (median)	1071	1531
deceased(%)	226(25.7%)	137(29.1%)
alive(%)	655(74.3%)	333(70.9%)

Table 1. Clinical information of RCC patients from TCGA and ICGC cohort.















































